Comparison of "sandwich chemo-radiotherapy" and six cycles of chemotherapy followed by adjuvant radiotherapy in patients with stage IIIC endometrial cancer: a single center experience

被引:6
|
作者
Dogan, Nasuh Utku [1 ]
Yavas, Guler [2 ]
Yavas, Cagdas [3 ]
Ata, Ozlem [4 ]
Yilmaz, Setenay Arzu [1 ]
Celik, Cetin [1 ]
机构
[1] Selcuk Univ, Fac Med, Dept Gynecol Oncol, Kadin Hastaliklari & Dogum AD, TR-42075 Selcuklu, Konya, Turkey
[2] Selcuk Univ, Fac Med, Dept Radiat Oncol, Konya, Turkey
[3] Konya Training & Res Hosp, Dept Radiat Oncol, Konya, Turkey
[4] Selcuk Univ, Fac Med, Dept Med Oncol, Konya, Turkey
关键词
Endometrial cancer; Sandwich chemotherapy; Radiotherapy; Acute toxicity; GYNECOLOGIC-ONCOLOGY-GROUP; RADIATION-THERAPY; CARBOPLATIN CHEMOTHERAPY; CARCINOMA PATIENTS; TRIAL; DOXORUBICIN; ADENOCARCINOMA; PACLITAXEL; CISPLATIN;
D O I
10.1007/s00404-013-2817-9
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
To compare "sandwich chemo-radiotherapy" with six cycles of chemotherapy followed by adjuvant radiotherapy with respect to tolerability and acute toxicity. Twenty-five women with surgically staged IIIC endometrial cancer were included. Treatment consisted of either three cycles of paclitaxel (175 mg/mA(2)) and carboplatin (AUC 6) on a q21-day schedule followed by irradiation (45-50.4 Gy) or six cycles of the same chemotherapy followed by radiotherapy. Acute toxicity related to either chemotherapy or radiotherapy was evaluated. Median age was 61.5 years (range 36-83 years). Eleven patients had sandwich chemo-radiotherapy, and the other 14 patients had 6 cycles of chemotherapy followed by radiotherapy. Three out of the five patients who could not complete all the cycles in the sandwich chemo-radiotherapy group had pelvic and para-aortic radiotherapy. Acute radiotherapy related grade 1-2 gastrointestinal system (GIS) and genitourinary system (GUS) toxicities were observed in 72.8 and 63.6 % of patients, respectively, for sandwich group. Undesired treatment breaks in the course of radiotherapy were observed in six patients for sandwich chemo-radiotherapy and in one patient receiving six cycles of chemotherapy followed by radiotherapy. All the patients who had undesired treatment breaks in the sandwich chemo-radiotherapy group had pelvic and para-aortic radiotherapy. Sandwich chemo-radiotherapy seems to be more toxic particularly for patients who had pelvic and para-aortic irradiation. Therefore, it might be more convenient to delay radiotherapy after six cycles of chemotherapy for patients with the indication of pelvic para-aortic radiotherapy.
引用
收藏
页码:845 / 850
页数:6
相关论文
共 50 条
  • [31] A randomized phase III study comparing neoadjuvant chemotherapy followed by concurrent chemo-radiotherapy with concurrent chemo-radiotherapy in Asian-Indian (South Asian) population with muscle invasive bladder cancer
    Jakhar, S. L.
    Sharma, S.
    Singh, G.
    Kothari, T.
    Sharma, N.
    Beniwal, S. K.
    Kumar, H. S.
    Sinwar, R.
    P, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 71 - 71
  • [32] Primary chemotherapy (pCT) followed by concomitant chemo-radiotherapy (CT/RT) in advanced oropharyngeal and hypopharyngeal cancer.
    Licitra, L
    Locati, LD
    Bareggi, C
    Fumagalli, E
    Cerrotta, AM
    Palazzi, M
    Grandi, C
    Guzzo, M
    Valagussa, P
    Gardani, G
    ANNALS OF ONCOLOGY, 2000, 11 : 90 - 90
  • [33] Analysis of adjuvant chemotherapy and radiotherapy for stage II endometroid type endometrial cancer.
    Alter, Raanan
    Adams, William
    Block, Alec
    Small, William
    Harkenrider, Matthew M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] To compare neoadjuvant concurrent chemo-radiotherapy followed by surgery and neoadjuvant chemotherapy followed by surgery in carcinoma esophagus patients: A single institutional study in the Indian population
    Purkayastha, Abhishek
    Sharma, Neelam
    Sundaram, Viswanath
    Jaiswal, Pradeep
    Husain, Azhar
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (03) : 675 - 683
  • [35] A single-centre experience of adjuvant Durvalumab in patients with Non-small cell lung cancer (NSCLC) treated with radical concurrent chemo-radiotherapy
    Hussnain, Ali
    Button, Mick
    Iqbal, Sahar Najmus
    Powell, Ceri
    Cox, Samantha
    Namelo, Clara
    Shaw, Paul
    Chan, Po
    LUNG CANCER, 2024, 190
  • [36] Systemic Effects of Radiotherapy and Concurrent Chemo-Radiotherapy in Head and Neck Cancer Patients-Comparison of Serum Metabolome Profiles
    Jelonek, Karol
    Krzywon, Aleksandra
    Jablonska, Patrycja
    Slominska, Ewa M.
    Smolenski, Ryszard T.
    Polanska, Joanna
    Rutkowski, Tomasz
    Mrochem-Kwarciak, Jolanta
    Skladowski, Krzysztof
    Widlak, Piotr
    METABOLITES, 2020, 10 (02)
  • [37] IS THERE A BENEFIT FROM ADJUVANT CHEMO-RADIOTHERAPY FOR THE PATIENTS WITH RESECTABLE GASTRIC CANCER? RESULTS OF THE STANDARDIZED MULTIMODAL TREATMENT
    Gajzer, Borut
    Potrc, Stojan
    Ivanecz, Arpad
    Horvat, Matjaz
    ANNALS OF ONCOLOGY, 2011, 22 : v51 - v52
  • [38] Selected inoperable oral cavity cancers may be salvaged using definitive radiotherapy (RT) and chemo-radiotherapy (CRT): A single center experience.
    Shenoy, Shashank
    Mallick, Ankita
    Pati, Sudipta
    Chatterjee, Sanjoy
    Mallick, Indranil
    RADIOTHERAPY AND ONCOLOGY, 2024, 192 : S108 - S109
  • [39] Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis
    da Cunha Colombo Bonadio, Renata Rodrigues
    Meira Velame Azevedo, Renata Gondim
    Harada, Guilherme
    Severino da Costa, Samantha Cabral
    Miranda, Vanessa Costa
    de Freitas, Daniela
    Abdo Filho, Elias
    de Oliveira Ferreira, Patricia Alves
    Gabrielli, Flavia
    Estevez Diz, Maria del Pilar
    JOURNAL OF GLOBAL ONCOLOGY, 2018, 4 : 1 - 8
  • [40] Induction chemotherapy (CT) followed by alternating chemo-radiotherapy (CT-RT) in stage IV undifferentiated nasopharyngeal carcinoma (UNPC)
    Pentimalli, S.
    Bacigalupo, A.
    Ponzanelli, A.
    Vigo, V.
    Benasso, M.
    Marcenaro, M.
    CorvA, R.
    Agostinelli, S.
    Vitale, V.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S343 - S343